JP2024535930A5 - - Google Patents

Info

Publication number
JP2024535930A5
JP2024535930A5 JP2024519706A JP2024519706A JP2024535930A5 JP 2024535930 A5 JP2024535930 A5 JP 2024535930A5 JP 2024519706 A JP2024519706 A JP 2024519706A JP 2024519706 A JP2024519706 A JP 2024519706A JP 2024535930 A5 JP2024535930 A5 JP 2024535930A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
variable region
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024519706A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024535930A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2022/051437 external-priority patent/WO2023049999A1/en
Publication of JP2024535930A publication Critical patent/JP2024535930A/ja
Publication of JP2024535930A5 publication Critical patent/JP2024535930A5/ja
Pending legal-status Critical Current

Links

JP2024519706A 2021-09-29 2022-09-28 Trop2発現腫瘍細胞を標的化する結合剤 Pending JP2024535930A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163249728P 2021-09-29 2021-09-29
US63/249,728 2021-09-29
US202263326572P 2022-04-01 2022-04-01
US63/326,572 2022-04-01
PCT/CA2022/051437 WO2023049999A1 (en) 2021-09-29 2022-09-28 Binding agents targeting trop2-expressing tumor cells

Publications (2)

Publication Number Publication Date
JP2024535930A JP2024535930A (ja) 2024-10-02
JP2024535930A5 true JP2024535930A5 (enExample) 2025-10-08

Family

ID=85780298

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024519706A Pending JP2024535930A (ja) 2021-09-29 2022-09-28 Trop2発現腫瘍細胞を標的化する結合剤

Country Status (10)

Country Link
US (4) US12662549B2 (enExample)
EP (1) EP4408893A4 (enExample)
JP (1) JP2024535930A (enExample)
KR (1) KR20240082383A (enExample)
AU (1) AU2022357634A1 (enExample)
CA (1) CA3231574A1 (enExample)
IL (1) IL311673A (enExample)
MX (1) MX2024003779A (enExample)
TW (1) TW202330605A (enExample)
WO (1) WO2023049999A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024003779A (es) 2021-09-29 2024-04-19 Kisoji Biotechnology Inc Agentes de union dirigidos a celulas tumorales que expresan trop2.
EP4688866A1 (en) * 2023-04-04 2026-02-11 Kisoji Biotechnology Inc. Binding agents targeting trop2-expressing tumor cells
WO2024051383A1 (zh) * 2023-07-28 2024-03-14 上海洛启生物医药技术有限公司 抗Trop2抗体、包含所述抗体的缀合物及其应用
WO2026059880A1 (en) * 2024-09-12 2026-03-19 Modernatx, Inc. Trop2 binding molecules, nucleic acids encoding same, and methods of use
CN122145634A (zh) * 2026-05-11 2026-06-05 上海荣昌生物科技有限公司 一种cd47抗体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201500220A1 (ru) 2010-05-17 2015-10-30 Ливтех, Инк. Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
WO2011155579A1 (ja) 2010-06-10 2011-12-15 北海道公立大学法人札幌医科大学 抗Trop-2抗体
US9427464B2 (en) 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
EP3256494A4 (en) 2015-02-10 2018-12-05 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
RU2758234C2 (ru) * 2017-03-27 2021-10-26 Иммьюномедикс, Инк. ЛЕЧЕНИЕ ТРИЖДЫ НЕГАТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ХАРАКТЕРИЗУЮЩЕГОСЯ ЭКСПРЕССИЕЙ Trop-2, С ПОМОЩЬЮ САЦИТУЗУМАБА ГОВИТЕКАНА И ИНГИБИТОРА Rad51
GB201811368D0 (en) * 2018-07-11 2018-08-29 Ucb Biopharma Sprl Antibody
CN112646038B (zh) * 2019-10-11 2025-06-03 迈威(上海)生物科技股份有限公司 抗人Trop-2抗体及其应用
CA3171363A1 (en) 2019-12-20 2021-06-24 Kisoji Biotechnology Inc. Polypeptides, protein complexes and method for making same
CN113527497B (zh) * 2020-04-16 2022-06-10 上海洛启生物医药技术有限公司 抗Trop2纳米抗体及其应用
CN112321715B (zh) * 2020-11-03 2022-05-10 博奥信生物技术(南京)有限公司 抗trop2纳米抗体及其制备方法和应用
CN114685669A (zh) 2020-12-30 2022-07-01 和铂医药(苏州)有限公司 结合trop2的抗体及其用途
MX2024003779A (es) 2021-09-29 2024-04-19 Kisoji Biotechnology Inc Agentes de union dirigidos a celulas tumorales que expresan trop2.

Similar Documents

Publication Publication Date Title
JP2025011178A5 (enExample)
JP2023509323A5 (enExample)
HRP20240626T1 (hr) Bispecifična antitijela protiv ceacam5 i cd3
JP2020501531A5 (enExample)
JP2012501626A5 (enExample)
JP2017500028A5 (enExample)
EP4155319A1 (en) 4-1bb binding protein and application thereof
JP2025092589A5 (enExample)
JP2021512107A5 (enExample)
CA2670039A1 (en) Novel antiproliferation antibodies
EP4154910A1 (en) Binding protein having h2l2 and hcab structures
JP2022512642A5 (enExample)
JP2024016024A5 (enExample)
JP2025513745A5 (enExample)
JP2024533457A5 (enExample)
US12577314B2 (en) Anti-BCMA/anti-4-1BB bispecific antibodies and uses thereof
AU2019306113B2 (en) Anti-human PD-L1 antibodies and their uses
JP2024536383A5 (enExample)
JP2024522075A5 (enExample)
CN119176876A (zh) 抗b7-h4抗体及其应用
JP2024540062A5 (enExample)
WO2022057910A1 (en) Combination therapies targeting c5ar and pd-1/pd-l1 pathways
JP2024522234A5 (enExample)
US20220265821A1 (en) Composition and methods of targeting the pre-b cell receptor for the treatment of leukemias and lymphomas
CN112472804A (zh) 特异性结合erbb3的抗体及其用途